Corgentech analgesic NDA tabbed for mid-’06
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Corgentech plans to submit an NDA in mid-2006 for its needleless lidocaine injection system ALGRX 3268, the firm says Feb. 21. The product is targeted at children undergoing medical procedures requiring venipunctures and intravenous line placements. "With an onset of action of one to three minutes, ALGRX 3268 provides a unique fast-acting, local anesthetic for reducing pain associated with peripheral venous access and I.V. insertion procedures in children," the company says. Corgentech estimates approximately 18 mil. relevant procedures occur each year. 3268 is the first of three pain relievers Corgentech plans on filing...